To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)10 yuan has to be paid more for mobile phone payment at a toll station in Changchun. The official has set up a joint investigation team. According to Jiupai News, on December 11th, a truck driver posted a message on the social platform, saying that when passing through Nanwaizi Toll Station on G102 National Road, the cash charge for the truck at the toll station is 30 yuan, and the payment by WeChat is 40 yuan. On December 13th, the staff of Changchun Highway Management Office told Green Hornet that the discipline inspection team of Jilin Provincial Highway Bureau, Changchun Municipal Transportation Bureau and Changchun Highway Management Office had formed a joint investigation team to investigate and rectify such problems in all toll stations within the jurisdiction of Changchun City. The staff said: "It is wrong for the toll collector to accept 30 yuan. That car is 40 yuan's car, and it is inaccurate to judge the model. The deputy stationmaster, the squad leader and the toll collector involved in the duty stopped working and were investigated. " "No matter whether it is less or more, it will be strictly dealt with." The staff member said that the investigation team will strictly investigate the problem of not charging according to the model of the toll station.Changshu Automobile Accessories: It is planned to invest 22.8 million yuan to set up a joint venture with Antonlin Investment Co., Ltd. Changshu Automobile Accessories announced that the company plans to set up a joint venture with Antonlin Investment Co., Ltd. in Wuhu City, Anhui Province, tentatively named Wuhu Antonlin Intelligent Cockpit System Co., Ltd., with an estimated total investment of 140 million yuan, including a registered capital of 57 million yuan. The company invested 22.8 million yuan, accounting for 40% of the total share capital of Antonglin in Wuhu; Antonglin Investment Co., Ltd. contributed 34.2 million yuan, accounting for 60% of the total share capital of Antonglin in Wuhu. The establishment of the new company will expand the company's industrial layout, improve the company's comprehensive competitive strength and realize the company's strategic plan for sustainable development.
Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Zhongwei Semiconductor launched the cost-effective touch MCU-CMS79FT72xB series, and Zhongwei Semiconductor (Shenzhen) Co., Ltd. continued to improve the resources of the 8-bit MCU product lineup and launched the cost-effective touch MCU-CMS79FT72xB. CMS79FT72xB series MCU has built-in 26-channel touch key detection circuit, working voltage is 2.5V~5.5V, working temperature range is -40℃~85℃, and it integrates ADC, LED, PWM, USART, LVD and other modules. Provide SOP16, SOP20 and SOP28 packages, which can flexibly meet the applications of household appliances, kitchen and bathroom appliances, household appliances, personal care and so on. At present, the CMS79FT72xB series has been mass-produced in Q4 of 2024, and the sample application has been opened. (Medium-micro semiconductor)Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.
Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Stock index futures continued to fall, and the main contract of SSE 50 Stock Index Futures (IH) fell by 2.00% in the day, and now it is reported at 2,653.6 points. The main contract of CSI 500 stock index futures (IC) fell by 2.00% in the day and is now reported at 5976.8 points.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14